Recent News
Amsterdam Court Gives no Substantive Ruling in Pharmaceutical Accountability Foundation-AbbVie Excessive Pricing Case on Humira
AMSTERDAM, 9 July 2025: The Amsterdam District Court declared the Pharmaceutical Accountability Foundation (PAF) inadmissible in its court case against AbbVie, and has thus not...
The Excessive Pricing Case Against AbbVie verdict will become available 9 July
Update following 9 May 2025 Hearing: Amsterdam District Court to decide on the merits of the case on 9 July 2025.
AMSTERDAM, THE NETHERLANDS: In February...
PAF – AbbVie Humira case comes to court May 9, 2025
Friday, May 9 (09:30-12:30), Farma ter Verantwoording and AbbVie will meet at the Amsterdam District Court, Parnassusweg 280, 1076 AV Amsterdam (near Amsterdam Zuid train...
€17m fine imposed to pharma pirate Leadiant upheld on appeal
AMSTERDAM, THE NETHERLANDS: The District Court of Rotterdam has rejected the appeal of pharmaceutical company Leadiant against the 2021 decision of the Netherlands Competition Authority...
The Lancet on the PAF AbbVie case: AbbVie to face potentially groundbreaking case over Humira
The Lancet interviewed the chair of the Pharmaceutical Accountability Foundation (Wilbert Bannenberg) about the recent verdict of the Amsterdam Court moving the case to the...
PRESS RELEASE: Lawsuit against AbbVie for abuse of economic dominance and violation of human rights moves to substantive phase
AbbVie's Humira pricing policy drained up to €1.2 billion from the Dutch healthcare system
AMSTERDAM, NETHERLANDS: Today the Amsterdam District Court ruled that the lawsuit filed...